C1071007 - MAGNETISMM-7 A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508897-27-00

Acronym

C1071007

Enrollment

377

Registered

2024-04-10

Start date

2022-04-28

Completion date

Unknown

Last updated

2025-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

 Progression-free survival (PFS) by Blinded Independent Central Review (BICR) per International Myeloma Working Group (IMWG)

Detailed description

 Minimal residual disease (MRD)-negative rate at 12 months after randomization per IMWG as assessed via next-generation sequencing (NGS)  Overall survival (OS)

Interventions

DRUGZelvina 15 mg hard capsules

DRUGZelvina 5 mg hard capsules

DRUGELRANATAMAB

DRUGZelvina 10 mg hard capsules

DRUGPrivigen 100 mg/ml solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
 Progression-free survival (PFS) by Blinded Independent Central Review (BICR) per International Myeloma Working Group (IMWG)	—

Secondary

Measure	Time frame
 Minimal residual disease (MRD)-negative rate at 12 months after randomization per IMWG as assessed via next-generation sequencing (NGS)  Overall survival (OS)	—

Countries

Austria, Belgium, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026